Increased CSF biomarkers of angiogenesis in Parkinson disease

Neurology

Volumn 85, Issue 21, 2015, Pages 1834-1842

  Janelidze, Shorena ^a   Lindqvist, Daniel ^b,c,e   Francardo, Veronica ^d   Hall, Sara ^b   Zetterberg, Henrik ^g,h   Blennow, Kaj ^g,i,j   Adler, Charles H ^k   Beach, Thomas G ^k   Serrano, Geidy E ^l   Van Westen, Danielle ^a,f   Londos, Elisabet ^a,f   Cenci, M Angela ^d   Hansson, Oskar ^a,f  

^a LUND UNIVERSITY   (Sweden)

^b Department of Clinical Sciences ^*  (Sweden)

^c Division of Psychiatry   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e Psychiatry Research Skåne   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g Institute of Neuroscience and Physiology   (Sweden)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j ROYAL SWEDISH ACADEMY OF SCIENCES   (Sweden)

^k MAYO CLINIC   (United States)

^l SUN HEALTH RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BIOLOGICAL MARKER; INTERLEUKIN 8; LEVODOPA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACENTAL GROWTH FACTOR; SERUM ALBUMIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENIC FACTOR;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANGIOGENESIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID ANALYSIS; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DIFFUSE LEWY BODY DISEASE; FEMALE; GAIT DISORDER; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROFILAMENT; ORTHOSTATIC BLOOD PRESSURE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; WHITE MATTER LESION; CEREBROSPINAL FLUID; NEOVASCULARIZATION, PATHOLOGIC; REPRODUCIBILITY;

AGED; ANGIOGENESIS INDUCING AGENTS; BIOMARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PARKINSON DISEASE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 84947944951     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002151     Document Type: Article

References (39)

1. Faucheux BA, Bonnet AM, Agid Y, Hirsch EC. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 1999;353:981-982.
2. Wada K, Arai H, Takanashi M, et al. Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease. Neuroreport 2006;17:705-709.
3. Barcia C, Bautista V, Sanchez-Bahillo A, et al. Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. J Neural Transm 2005;112: 1237-1248.
4. Desai Bradaric B, Patel A, Schneider JA, Carvey PM, Hendey B. Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy. J Neural Transm 2012;119:59-71.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
6. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27:552-558.
7. Kiefer F, Siekmann AF. The role of chemokines and their receptors in angiogenesis. Cell Mol Life Sci 2011;68: 2811-2830.
8. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
9. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707; quiz 1837.
10. Hertze J, Nagga K, Minthon L, Hansson O. Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. BMC Neurol 2014;14:64.
11. Lindqvist D, Hall S, Surova Y, et al. Cerebrospinal fluid inflammatory markers in Parkinson's disease: associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013;33:183-189.
12. Zetterberg H, Jakobsson J, Redsater M, et al. Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res 2014;217:143-146.
13. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993-997.
14. Kendall RL, Thomas KA. Inhibition of vascular endothe-lial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90:10705-10709.
15. Qi JW, Qin TT, Xu LX, et al. TNFSF15 inhibits vascu-logenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1. Proc Natl Acad Sci USA 2013;110:13863-13868.
16. Kruit MC, Thijs RD, Ferrari MD, Launer LJ, van Buchem MA, van Dijk JG. Syncope and orthostatic intolerance increase risk of brain lesions in migraineurs and controls. Neurology 2013;80:1958-1965.
17. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1:426-436.
18. Blennow K, Hampel H, Weiner M, Zetterberg H. Cere-brospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-144.
19. Skillback T, Zetterberg H, Blennow K, Mattsson N. Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5, 542 clinical samples. Alzheimers Res Ther 2013;5:47.
20. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445-1452.
21. Yao Y, Tsirka SE. Monocyte chemoattractant protein-1 and the blood-brain barrier. Cell Mol Life Sci 2014;71:683-697.
22. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One 2012;7:e30525.
23. Ohlin KE, Francardo V, Lindgren HS, et al. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 2011;134:2339-2357.
24. Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005;57:176-179.
25. Pisani V, Stefani A, Pierantozzi M, et al. Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J Neuroinflammation 2012;9:188.
26. Argaw AT, Asp L, Zhang J, et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 2012;122:2454-2468.
27. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437:497-504.
28. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57: 178-201.
29. Rite I, Machado A, Cano J, Venero JL. Blood-brain barrier disruption induces in vivo degeneration of nigral dopamin-ergic neurons. J Neurochem 2007;101:1567-1582.
30. Marteau L, Valable S, Divoux D, et al. Angiopoietin-2 is vasoprotective in the acute phase of cerebral ischemia. J Cereb Blood Flow Metab 2013;33:389-395.
31. Yates PA, Villemagne VL, Ellis KA, Desmond PM, Masters CL, Rowe CC. Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Front Neurol 2014;4:205.
32. Dassan P, Brown MM, Gregoire SM, Keir G, Werring DJ. Association of cerebral microbleeds in acute ischemic stroke with high serum levels of vascular endothelial growth factor. Arch Neurol 2012;69:1186-1189.
33. Novak V, Novak P, Spies JM, Low PA. Autoregulation of cerebral blood flow in orthostatic hypotension. Stroke 1998;29:104-111.
34. Vokatch N, Grotzsch H, Mermillod B, Burkhard PR, Sztajzel R. Is cerebral autoregulation impaired in Parkin son's disease? A transcranial Doppler study. J Neurol Sci 2007;254:49-53.
35. Kim YW, Byzova TV. Oxidative stress in angiogenesis and vascular disease. Blood 2014;123:625-631.
36. Oh YS, Kim JS, Lee KS. Orthostatic and supine blood pressures are associated with white matter hyperintensities in Parkinson disease. J Mov Disord 2013;6:23-27.
37. Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nat Rev Neurol 2011;7:229-236.
38. Argaw AT, Zhang Y, Snyder BJ, et al. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol 2006;177:5574-5584.
39. Loeffler S, Fayard B, Weis J, Weissenberger J. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 2005;115:202-213.